NF-κB is a potential pharmacological target in triple negative breast cancers.

Triple negative breast cancers (TNBCs), characterized by lack of estrogen, progesterone and HER2 receptors, are a highly heterogenous group of tumors which account for about 20% to 25% of all breast cancers. TNBCs are often associated with epithelial-mesenchymal transition and a high propensity for early metastasis. Since no molecularly-targeted therapeutic agents are clinically available for TNBCs, these tumors, which are frequently resistant to cytotoxic chemotherapy, remain difficult to treat. Nevertheless, progress is being made in the finding of molecular alterations typical of TNBCs toward which to focus therapeutic efforts.